{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RCUS/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T00:47:56.102Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4275,"canonical_name":"Arcus Biosciences, Inc.","cik":"0001724521","uei":null,"lei":null,"duns":null,"ticker":"RCUS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35,"clinical":10},"count":45,"timeline":[{"ts":"2026-09-28","kind":"sec.filing","form_type":"CT ORDER","title":"CT ORDER — Arcus Biosciences, Inc. — 2026-09-28","url_slug":"/sec/cik-0001724521/ct-order/9999999997-26-001556","accession_number":"9999999997-26-001556","importance":30},{"ts":"2026-09-04","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07751250","excerpt":"[\"Healthy Participants\",\"Hepatic Impairment\"]","importance":30},{"ts":"2026-08-25","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07662057","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-08-24","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-08-24","url_slug":"/sec/cik-0001724521/4/0001771961-26-000006","accession_number":"0001771961-26-000006","importance":30},{"ts":"2026-08-21","kind":"sec.filing","form_type":"144","title":"144 — Arcus Biosciences, Inc. — 2026-08-21","url_slug":"/sec/cik-0001724521/144/0001950047-26-008535","accession_number":"0001950047-26-008535","importance":30},{"ts":"2026-08-13","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07641881","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Arcus Biosciences, Inc. — 2026-08-07","url_slug":"/sec/cik-0001724521/schedule-13d-a/0001104659-26-092737","accession_number":"0001104659-26-092737","importance":70},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Arcus Biosciences, Inc. — 2026-08-05","url_slug":"/sec/cik-0001724521/10-q/0001724521-26-000044","accession_number":"0001724521-26-000044","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Arcus Biosciences, Inc. — 2026-08-05","url_slug":"/sec/cik-0001724521/8-k/0001724521-26-000042","accession_number":"0001724521-26-000042","importance":35},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":19799,"price_per_share":28.608,"usd_value":566410,"security_title":"Common Stock","importance":35.566409792},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":268,"price_per_share":29.397,"usd_value":7878,"security_title":"Common Stock","importance":35.007878396},{"ts":"2026-07-09","kind":"sec.form144","reporter":"Juan Jaen","title":"Officer","shares":25000,"usd_value":749000,"security_title":"Class A Common Stock","approx_sale_date":"2026-07-09","accession_number":"0001958244-26-000445","importance":40.1498},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":48502,"price_per_share":30.053,"usd_value":1457631,"security_title":"Common Stock","importance":36.457630606},{"ts":"2026-06-24","kind":"sec.form144","reporter":"Juan Jaen","title":"Officer","shares":50000,"usd_value":1440000,"security_title":"Class A Common Stock","approx_sale_date":"2026-06-24","accession_number":"0001958244-26-000402","importance":40.288},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":6431,"price_per_share":29.6595,"usd_value":190740,"security_title":"Common Stock","importance":35.1907402445},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":14067,"price_per_share":27.6875,"usd_value":389480,"security_title":"Common Stock","importance":35.3894800625},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":1697,"price_per_share":28.0612,"usd_value":47620,"security_title":"Common Stock","importance":35.0476198564},{"ts":"2026-06-22","kind":"sec.form144","reporter":"Juan Jaen","title":"Officer","shares":25000,"usd_value":680750,"security_title":"Class A Common Stock","approx_sale_date":"2026-06-22","accession_number":"0001958244-26-000398","importance":40.13615},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Jaen Juan C.","title":"President","shares":9236,"price_per_share":27.0313,"usd_value":249661,"security_title":"Common Stock","importance":35.2496610868},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Arcus Biosciences, Inc. — 2026-06-12","url_slug":"/sec/cik-0001724521/8-k/0001724521-26-000037","accession_number":"0001724521-26-000037","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Lacey David L. — 2026-06-12","url_slug":"/sec/cik-0001734422/4/0001734422-26-000005","accession_number":"0001734422-26-000005","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-06-12","url_slug":"/sec/cik-0001724521/4/0001836662-26-000005","accession_number":"0001836662-26-000005","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-06-12","url_slug":"/sec/cik-0001724521/4/0001770252-26-000003","accession_number":"0001770252-26-000003","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-06-12","url_slug":"/sec/cik-0001724521/4/0001792164-26-000006","accession_number":"0001792164-26-000006","importance":30},{"ts":"2026-06-11","kind":"sec.insider.m","reporter":"Tang Carolyn C.","title":"General Counsel","shares":34090,"price_per_share":2.574,"usd_value":87748,"security_title":"Common Stock","importance":15.08774766},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"PERLMAN ANDREW J","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"FALBERG KATHRYN E","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"KANEKO YASUNORI","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Machado Patrick","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Lacey David L.","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Lambert Nicole","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Ribas Antoni","title":null,"shares":5700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.form144","reporter":"ALEXANDER AZOY","title":"Officer","shares":2562,"usd_value":64921,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005400","importance":40.012984216},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Azoy Alexander","title":"Chief Accounting Officer","shares":2562,"price_per_share":25.7704,"usd_value":66024,"security_title":"Common Stock","importance":35.0660237648},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — Arcus Biosciences, Inc. — 2026-06-01","url_slug":"/sec/cik-0001724521/144/0001950047-26-005400","accession_number":"0001950047-26-005400","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-06-01","url_slug":"/sec/cik-0001724521/4/0001771961-26-000004","accession_number":"0001771961-26-000004","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — Arcus Biosciences, Inc. — 2026-05-12","url_slug":"/sec/cik-0001724521/4/0001792164-26-000003","accession_number":"0001792164-26-000003","importance":30},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Goeltz II Robert C.","title":"Chief Financial Officer","shares":7763,"price_per_share":25.63,"usd_value":198966,"security_title":"Common Stock","importance":35.19896569},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06608927","excerpt":"[\"Metastatic Pancreatic Ductal Adenocarcinoma\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05568095","excerpt":"[\"Advanced Upper Gastrointestinal Tract Adenocarcinoma\"]","importance":60},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04736173","excerpt":"[\"Non Small Cell Lung Cancer\",\"Nonsquamous Non Small Cell Lung Cancer\",\"Squamous Non Small Cell Lung Cancer\",\"Lung Cancer\"]","importance":45},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05536141","excerpt":"[\"Clear Cell Renal Cell Carcinoma\",\"Solid Tumors\"]","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07364214","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06120075","excerpt":"[\"Advanced Cancer\"]","importance":30},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Arcus Biosciences, Inc.","title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05329766","excerpt":"[\"Gastrointestinal Tract Malignancies\"]","importance":45}]}